Henry Schein, Inc. (NASDAQ: HSIC), the world’s largest provider of health care solutions to office-based dental and medical practitioners, recently announced the successful completion of a strategic investment by funds affiliated with KKR, a leading global investment firm. This transaction amounted to a substantial $250 million, resulting in KKR obtaining approximately 12% of the common shares of Henry Schein.
As a result of this investment, William K. “Dan” Daniel, executive advisor to KKR and former executive vice president of Danaher Corporation, has officially joined Henry Schein’s board of directors as an independent director. He joins Max Lin, partner at KKR and leader of the firm’s health care industry team in the Americas, who became a member of Henry Schein’s board of directors on May 2, 2025.
Henry Schein's sales reached $12.7 billion in 2024, marking a compound annual growth rate of approximately 11.2% since the company became a public entity in 1995. This growth is a testament to the company's commitment to delivering value to its stakeholders.
Stanley M. Bergman, Chairman of the Board and Chief Executive Officer of Henry Schein, expressed his pleasure in welcoming Max and Dan to the board, highlighting their extensive experience in health care, operations, and strategic growth and their potential to contribute significantly as the company pursues its bold+1 strategy.
These developments underscore Henry Schein's commitment to leveraging strategic investments and experienced leadership to drive long-term value and advance its position as a leading solutions company for health care professionals. As a result of these announcements, the company's shares have moved 0.71% on the market, and are now trading at a price of $72.05. If you want to know more, read the company's complete 8-K report here.
